ES2310601T3 - Preparaciones oftalmicas antimicrobianas, sinergicas, que contienen clorito y peroxido de hidrogeno. - Google Patents
Preparaciones oftalmicas antimicrobianas, sinergicas, que contienen clorito y peroxido de hidrogeno. Download PDFInfo
- Publication number
- ES2310601T3 ES2310601T3 ES02756279T ES02756279T ES2310601T3 ES 2310601 T3 ES2310601 T3 ES 2310601T3 ES 02756279 T ES02756279 T ES 02756279T ES 02756279 T ES02756279 T ES 02756279T ES 2310601 T3 ES2310601 T3 ES 2310601T3
- Authority
- ES
- Spain
- Prior art keywords
- chlorite
- use according
- weight
- eye
- peroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229910001919 chlorite Inorganic materials 0.000 title claims abstract description 61
- 229910052619 chlorite group Inorganic materials 0.000 title claims abstract description 61
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 24
- 230000002195 synergetic effect Effects 0.000 title description 4
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 52
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims abstract description 51
- -1 chlorite compound Chemical class 0.000 claims abstract description 25
- 229910052751 metal Inorganic materials 0.000 claims abstract description 12
- 239000002184 metal Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000011575 calcium Substances 0.000 claims abstract 3
- 229910052791 calcium Inorganic materials 0.000 claims abstract 3
- 239000011777 magnesium Substances 0.000 claims abstract 3
- 229910052749 magnesium Inorganic materials 0.000 claims abstract 3
- 239000011591 potassium Substances 0.000 claims abstract 3
- 229910052700 potassium Inorganic materials 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 206010023332 keratitis Diseases 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 231100000776 exotoxin Toxicity 0.000 claims description 5
- 239000002095 exotoxin Substances 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 206010062028 Keratitis bacterial Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 15
- 239000004599 antimicrobial Substances 0.000 abstract description 7
- 208000001860 Eye Infections Diseases 0.000 abstract description 2
- 208000011323 eye infectious disease Diseases 0.000 abstract description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 88
- 239000000243 solution Substances 0.000 description 54
- 239000004155 Chlorine dioxide Substances 0.000 description 44
- 235000019398 chlorine dioxide Nutrition 0.000 description 44
- 238000011282 treatment Methods 0.000 description 43
- 208000025865 Ulcer Diseases 0.000 description 29
- 150000002978 peroxides Chemical class 0.000 description 27
- 238000009472 formulation Methods 0.000 description 25
- 201000004681 Psoriasis Diseases 0.000 description 24
- 239000002253 acid Substances 0.000 description 21
- 231100000397 ulcer Toxicity 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 239000000645 desinfectant Substances 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 14
- 206010013774 Dry eye Diseases 0.000 description 14
- 238000004140 cleaning Methods 0.000 description 14
- 210000004087 cornea Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 208000002205 allergic conjunctivitis Diseases 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 230000002500 effect on skin Effects 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 229960002218 sodium chlorite Drugs 0.000 description 9
- 230000036269 ulceration Effects 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 208000024998 atopic conjunctivitis Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000004927 skin cell Anatomy 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010011985 Decubitus ulcer Diseases 0.000 description 4
- 208000035874 Excoriation Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000000558 Varicose Ulcer Diseases 0.000 description 4
- 238000005299 abrasion Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229910001882 dioxygen Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 230000001185 psoriatic effect Effects 0.000 description 4
- IZMWMZZLBDFQKK-UHFFFAOYSA-M sodium;hydrogen peroxide;chlorite Chemical compound [Na+].OO.[O-]Cl=O IZMWMZZLBDFQKK-UHFFFAOYSA-M 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000607 artificial tear Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003641 microbiacidal effect Effects 0.000 description 3
- 229940124561 microbicide Drugs 0.000 description 3
- 239000002855 microbicide agent Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- VKJKEPKFPUWCAS-UHFFFAOYSA-M potassium chlorate Chemical compound [K+].[O-]Cl(=O)=O VKJKEPKFPUWCAS-UHFFFAOYSA-M 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010062542 Arterial insufficiency Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000003260 anti-sepsis Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001639 boron compounds Chemical class 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- NHYCGSASNAIGLD-UHFFFAOYSA-N Chlorine monoxide Chemical class Cl[O] NHYCGSASNAIGLD-UHFFFAOYSA-N 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010048649 Koebner phenomenon Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LUVHQTUYWUPFAS-UHFFFAOYSA-N [Cr].[Hg] Chemical compound [Cr].[Hg] LUVHQTUYWUPFAS-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229910001902 chlorine oxide Inorganic materials 0.000 description 1
- 229940077239 chlorous acid Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010018797 guttate psoriasis Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100001032 irritation of the eye Toxicity 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- RYZCLUQMCYZBJQ-UHFFFAOYSA-H lead(2+);dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Pb+2].[Pb+2].[Pb+2].[O-]C([O-])=O.[O-]C([O-])=O RYZCLUQMCYZBJQ-UHFFFAOYSA-H 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 210000002073 venous valve Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US911638 | 2001-07-23 | ||
| US09/911,638 US6592907B2 (en) | 1999-10-04 | 2001-07-23 | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2310601T3 true ES2310601T3 (es) | 2009-01-16 |
Family
ID=25430605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02756279T Expired - Lifetime ES2310601T3 (es) | 2001-07-23 | 2002-06-24 | Preparaciones oftalmicas antimicrobianas, sinergicas, que contienen clorito y peroxido de hidrogeno. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6592907B2 (https=) |
| EP (1) | EP1418881B1 (https=) |
| JP (1) | JP5002114B2 (https=) |
| AT (1) | ATE402712T1 (https=) |
| AU (1) | AU2002322298A1 (https=) |
| DE (1) | DE60227960D1 (https=) |
| ES (1) | ES2310601T3 (https=) |
| MX (1) | MXPA04000764A (https=) |
| WO (1) | WO2003009802A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070104798A1 (en) | 1999-10-04 | 2007-05-10 | S.K. Pharmaceuticals, Inc. | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |
| US6592907B2 (en) * | 1999-10-04 | 2003-07-15 | Hampar L. Karagoezian | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
| US20040037891A1 (en) * | 1999-10-04 | 2004-02-26 | Karagoezian Hampar L. | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
| US20070110782A1 (en) * | 2000-11-08 | 2007-05-17 | Fxs Ventures, Llc | L-histidine in ophthalmic solutions |
| US20040009238A1 (en) * | 2002-07-09 | 2004-01-15 | Chris Miller | Exogenenous nitric oxide gas (gNO) therapy in wound healing |
| US7112334B2 (en) * | 2001-06-05 | 2006-09-26 | Freiberg Roberta C | Allergy inhibition |
| US20030133893A1 (en) * | 2002-01-15 | 2003-07-17 | Degania Silicone Ltd. | Compositions and methods for treating skin ailments |
| US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
| JP2007516224A (ja) * | 2003-05-12 | 2007-06-21 | ジョンソンディバーシー・インコーポレーテッド | 二酸化塩素を生成及び分配する方法（ｓｙｓｔｅｍ） |
| US20050281890A1 (en) * | 2004-06-18 | 2005-12-22 | San Chandan K | Methods and compositions for wound healing |
| CA2602522C (en) | 2005-03-23 | 2014-09-09 | Oculus Innovative Sciences, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| ITMI20051569A1 (it) * | 2005-08-11 | 2007-02-12 | Biokosmes S R L | Composizione cicatrizzante |
| EP1993571B1 (en) | 2006-01-20 | 2018-07-25 | Sonoma Pharmaceuticals, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| US20070264226A1 (en) * | 2006-05-10 | 2007-11-15 | Karagoezian Hampar L | Synergistically enhanced disinfecting solutions |
| GB0705179D0 (en) * | 2007-03-17 | 2007-04-25 | Syntopix Ltd | Formulations |
| RU2376038C2 (ru) * | 2007-11-19 | 2009-12-20 | Государственное образовательное учреждение высшего профессионального образования Военно-медицинская академия им. С.М. Кирова | Способ изготовления лечебной мягкой контактной линзы |
| US20090239954A1 (en) * | 2008-03-19 | 2009-09-24 | Collins Gary L | Phosphate buffered ophthalmic solutions displaying improved efficacy |
| US20100106079A1 (en) * | 2008-06-03 | 2010-04-29 | Oculus Innovative Sciences, Inc. | Method and apparatus for treating a wound |
| US20100226999A1 (en) * | 2009-03-06 | 2010-09-09 | Tracy Quevillon-Coleman | Process for forming stabilized ophthalmic solutions |
| WO2010148004A1 (en) | 2009-06-15 | 2010-12-23 | Oculus Innovative Sciences, Inc. | Solution containing hypochlorous acid and methods of using same |
| US20120329117A1 (en) * | 2010-12-20 | 2012-12-27 | E.I. Du Pont De Nemours And Company | Control of contaminant microorganisms in fermentation processes with synergistic formulations containing stabilized chlorine dioxide and peroxide compound |
| DE102010055771A1 (de) | 2010-12-23 | 2012-06-28 | KyroChem GmbH | Chlorithaltige Zusammensetzung |
| US8846107B2 (en) | 2010-12-29 | 2014-09-30 | Ecolab Usa Inc. | In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof |
| EP2687094B1 (en) | 2010-12-29 | 2018-05-02 | Ecolab USA Inc. | Generation of peroxcarboxylic acids at alkaline pH, and their use as textile bleaching and antimicrobial agents |
| US9321664B2 (en) | 2011-12-20 | 2016-04-26 | Ecolab Usa Inc. | Stable percarboxylic acid compositions and uses thereof |
| EP2831000A4 (en) | 2012-03-30 | 2016-03-30 | Ecolab Usa Inc | USE OF PERCONDIC ACID / HYDROGEN PEROXIDE AND PEROXIDE REDUCERS FOR THE TREATMENT OF DRILLING LIQUIDS, FRACKING LIQUIDS, REFILL WATER AND DISPOSAL WATER |
| US10844322B2 (en) * | 2012-08-07 | 2020-11-24 | Ecolab Usa Inc. | High flashpoint alcohol-based cleaning, sanitizing and disinfecting composition and method of use on food contact surfaces |
| AU2013314303B2 (en) | 2012-09-12 | 2018-01-18 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US20140256811A1 (en) | 2013-03-05 | 2014-09-11 | Ecolab Usa Inc. | Efficient stabilizer in controlling self accelerated decomposition temperature of peroxycarboxylic acid compositions with mineral acids |
| US10165774B2 (en) | 2013-03-05 | 2019-01-01 | Ecolab Usa Inc. | Defoamer useful in a peracid composition with anionic surfactants |
| US8822719B1 (en) | 2013-03-05 | 2014-09-02 | Ecolab Usa Inc. | Peroxycarboxylic acid compositions suitable for inline optical or conductivity monitoring |
| WO2015138604A1 (en) | 2014-03-12 | 2015-09-17 | University Of Virginia Patent Foundation | Compositions and methods for treating eye infections and disease |
| EP3154413B1 (en) * | 2014-06-15 | 2021-08-25 | Yeda Research and Development Co. Ltd. | Surface treatment of contact lens and treatment of ocular discomfort by water soluble polymers and lipids/liposomes |
| CA3058097C (en) * | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| CA3062394A1 (en) | 2017-05-04 | 2018-11-08 | Walter SCHAUB | Compositions and treatment procedures for the treatment of pathogenic infections |
| SG11202006664UA (en) | 2018-01-14 | 2020-08-28 | Collidion Inc | Compositions, kits, methods and uses for cleaning, disinfecting, sterilizing and/or treating |
| EP3841059A1 (en) | 2018-08-22 | 2021-06-30 | Ecolab USA Inc. | Hydrogen peroxide and peracid stabilization with molecules based on a pyridine carboxylic acid at c-3, -4 or -5 |
| CN113811762A (zh) | 2019-05-31 | 2021-12-17 | 埃科莱布美国股份有限公司 | 通过电导率测量和过酸组合物监测过酸浓度的方法 |
| WO2021026410A1 (en) | 2019-08-07 | 2021-02-11 | Ecolab Usa Inc. | Polymeric and solid-supported chelators for stabilization of peracid-containing compositions |
| CA3167941A1 (en) | 2020-02-14 | 2021-08-19 | Collidion, Inc. | Compositions, kits, methods and uses for cleaning, disinfecting, sterilizing and/or treating |
| KR102795876B1 (ko) * | 2024-06-24 | 2025-04-17 | 셀미트주식회사 | 항생제 대체 조성물 및 이의 제조방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3585147A (en) | 1969-10-01 | 1971-06-15 | Int Dioxcide Inc | Stabilized chlorine dioxide solutions containing a chloride and processes of making and using same |
| US4317814A (en) | 1980-06-12 | 1982-03-02 | Felipe Laso | Preparation and method for treating burns |
| US4670185A (en) | 1982-07-19 | 1987-06-02 | Lion Corporation | Aqueous vesicle dispersion having surface charge |
| US4574084A (en) * | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
| US4756844A (en) * | 1986-12-29 | 1988-07-12 | The Dow Chemical Company | Controlled-release composition having a membrane comprising submicron particles |
| US4891216A (en) | 1987-04-14 | 1990-01-02 | Alcide Corporation | Disinfecting compositions and methods therefor |
| US5607698A (en) * | 1988-08-04 | 1997-03-04 | Ciba-Geigy Corporation | Method of preserving ophthalmic solution and compositions therefor |
| US4880638A (en) * | 1988-08-23 | 1989-11-14 | Bioxy International, Ltd. | Biocidal composition and method for disinfecting articles |
| US5279673A (en) * | 1990-01-05 | 1994-01-18 | Allergan, Inc. | Methods to disinfect contact lenses |
| US4997626A (en) * | 1990-01-05 | 1991-03-05 | Allergan, Inc. | Methods to disinfect contact lenses |
| US5246662A (en) * | 1989-10-02 | 1993-09-21 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
| US5078908A (en) | 1989-10-02 | 1992-01-07 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
| US5152912A (en) * | 1990-01-05 | 1992-10-06 | Allergan, Inc. | Chlorine dioxide precursor containing compositions useful in disinfecting contact lenses |
| US5145644A (en) * | 1990-12-20 | 1992-09-08 | Allergan, Inc. | Hydrogen peroxide destroying compositions and methods of making and using same |
| US5281353A (en) * | 1991-04-24 | 1994-01-25 | Allergan, Inc. | Compositions and methods for disinfecting/cleaning of lenses and for destroying oxidative disinfectants |
| US5270002A (en) * | 1991-10-03 | 1993-12-14 | Allergan, Inc. | Apparatus and method useful in disinfecting contact lenses |
| EP0674532B1 (en) * | 1992-12-17 | 2003-05-28 | Advanced Medical Optics, Inc. | Contact lens disinfecting solution containing an oxidizing agent and polyvinyl pyrrolidone |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| US5639481A (en) * | 1994-10-17 | 1997-06-17 | Symbollon Corporation | Method for the therapeutic treatment of a mammalian eye using an admixed composition containing free molecular iodine |
| US5855922A (en) | 1995-12-07 | 1999-01-05 | Bio-Cide International, Inc. | Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders |
| US6096328A (en) * | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
| US6033704A (en) * | 1998-08-14 | 2000-03-07 | Charvid Limited Liability Co. | Method and apparatus for preserving fruits and vegetables |
| EP1119347B1 (en) * | 1998-10-08 | 2005-03-02 | Hampar L. Karagoezian | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide |
| US6592907B2 (en) * | 1999-10-04 | 2003-07-15 | Hampar L. Karagoezian | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
-
2001
- 2001-07-23 US US09/911,638 patent/US6592907B2/en not_active Expired - Lifetime
-
2002
- 2002-06-24 MX MXPA04000764A patent/MXPA04000764A/es active IP Right Grant
- 2002-06-24 AT AT02756279T patent/ATE402712T1/de not_active IP Right Cessation
- 2002-06-24 JP JP2003515195A patent/JP5002114B2/ja not_active Expired - Fee Related
- 2002-06-24 DE DE60227960T patent/DE60227960D1/de not_active Expired - Lifetime
- 2002-06-24 AU AU2002322298A patent/AU2002322298A1/en not_active Abandoned
- 2002-06-24 EP EP02756279A patent/EP1418881B1/en not_active Expired - Lifetime
- 2002-06-24 WO PCT/US2002/019951 patent/WO2003009802A2/en not_active Ceased
- 2002-06-24 ES ES02756279T patent/ES2310601T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04000764A (es) | 2005-02-17 |
| EP1418881A4 (en) | 2006-07-05 |
| JP5002114B2 (ja) | 2012-08-15 |
| DE60227960D1 (de) | 2008-09-11 |
| ATE402712T1 (de) | 2008-08-15 |
| US20020064565A1 (en) | 2002-05-30 |
| EP1418881B1 (en) | 2008-07-30 |
| WO2003009802A3 (en) | 2003-11-27 |
| US6592907B2 (en) | 2003-07-15 |
| WO2003009802A2 (en) | 2003-02-06 |
| JP2004536137A (ja) | 2004-12-02 |
| EP1418881A2 (en) | 2004-05-19 |
| AU2002322298A1 (en) | 2003-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2310601T3 (es) | Preparaciones oftalmicas antimicrobianas, sinergicas, que contienen clorito y peroxido de hidrogeno. | |
| ES2551120T3 (es) | Preparaciones antimicrobianas sinérgicas que contienen peróxido de clorito y de hidrógeno | |
| EP1119347B1 (en) | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide | |
| US7648716B2 (en) | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide | |
| US20070264226A1 (en) | Synergistically enhanced disinfecting solutions | |
| MXPA06000228A (es) | Antibioticos de oxazolidinona sustituidos con un grupo ciclopropilo y derivados de los mismos. | |
| JP4727816B2 (ja) | 亜塩素酸塩と過酸化水素とを含有する共同作用抗菌性皮膚科・眼科製剤 | |
| HK1139560A (en) | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |